Background  	Background  	 NN	O
With  	With  	 IN	O
the  	the  	 DT	O
publication  	publication  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
Antihypertensive  	Antihypertensive  	 NNP	B-NP
and  	and  	 CC	O
Lipid-Lowering  	Lipid-Lowering  	 NNP	B-NP
Treatment  	Treatment  	 NNP	I-NP
to  	to  	 TO	O
prevent  	prevent  	 VB	O
Heart  	Heart  	 NNP	B-NP
Attack  	Attack  	 NNP	I-NP
Trial  	Trial  	 NNP	I-NP
( 	( 	 -LRB-	O
ALLHAT 	ALLHAT 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
the  	the  	 DT	O
role  	role  	 NN	O
of  	of  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
hypertension  	hypertension  	 NN	O
has  	has  	 VBZ	O
become  	become  	 VBN	O
controversial 	controversial 	 JJ	O
.  	.  	 .	O
The  	The  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
arm  	arm  	 NN	I-NP
of  	of  	 IN	I-NP
ALLHAT  	ALLHAT  	 NNP	I-NP
was  	was  	 VBD	O
stopped  	stopped  	 VBN	O
early 	early 	 RB	O
,  	,  	 ,	O
due  	due  	 JJ	O
to  	to  	 TO	O
a  	a  	 DT	O
doubling  	doubling  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
congestive  	congestive  	 JJ	B-NP
heart  	heart  	 NN	I-NP
failure  	failure  	 NN	I-NP
in  	in  	 IN	O
this  	this  	 DT	O
group 	group 	 NN	O
,  	,  	 ,	O
as  	as  	 RB	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
low-dose  	low-dose  	 JJ	B-NP
chlorthalidone  	chlorthalidone  	 JJ	I-NP
arm  	arm  	 NN	I-NP
[  	[  	 -LRB-	O
1  	1  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Prior  	Prior  	 RB	O
to  	to  	 TO	O
this  	this  	 DT	O
publication 	publication 	 NN	O
,  	,  	 ,	O
there  	there  	 EX	O
had  	had  	 VBD	O
been  	been  	 VBN	O
no  	no  	 DT	O
obvious  	obvious  	 JJ	O
suggestion  	suggestion  	 NN	O
of  	of  	 IN	O
a  	a  	 DT	O
mechanism  	mechanism  	 NN	O
by  	by  	 IN	O
which  	which  	 WDT	O
peripheral  	peripheral  	 VBD	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
in  	in  	 IN	O
general  	general  	 JJ	O
or  	or  	 CC	O
doxazosin  	doxazosin  	 NN	B-NP
in  	in  	 IN	O
particular  	particular  	 JJ	O
would  	would  	 MD	O
be  	be  	 VB	O
inferior  	inferior  	 JJ	O
to  	to  	 TO	O
chlorthalidone  	chlorthalidone  	 VB	O
or  	or  	 CC	O
would  	would  	 MD	O
specifically  	specifically  	 RB	O
cause  	cause  	 VB	O
CHF 	CHF 	 NNP	B-NP
.  	.  	 .	O
Because  	Because  	 IN	O
ALLHAT  	ALLHAT  	 NNP	B-NP
is  	is  	 VBZ	O
an  	an  	 DT	O
active-control  	active-control  	 JJ	B-NP
trial 	trial 	 NN	I-NP
,  	,  	 ,	O
no  	no  	 DT	O
inferences  	inferences  	 NNS	O
can  	can  	 MD	O
be  	be  	 VB	O
made  	made  	 VBN	O
on  	on  	 IN	O
whether  	whether  	 IN	O
this  	this  	 DT	O
increased  	increased  	 JJ	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
CHF  	CHF  	 NNP	B-NP
results  	results  	 NNS	O
from  	from  	 IN	O
a  	a  	 DT	O
harmful  	harmful  	 JJ	B-NP
effect  	effect  	 NN	I-NP
of  	of  	 IN	I-NP
doxazosin 	doxazosin 	 NN	I-NP
,  	,  	 ,	O
a  	a  	 DT	O
beneficial  	beneficial  	 JJ	O
effect  	effect  	 NN	O
of  	of  	 IN	O
chlorthalidone 	chlorthalidone 	 NN	B-NP
,  	,  	 ,	O
or  	or  	 CC	O
both 	both 	 DT	O
.  	.  	 .	O
Nonetheless 	Nonetheless 	 RB	O
,  	,  	 ,	O
there  	there  	 EX	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
a  	a  	 DT	O
large  	large  	 JJ	O
body  	body  	 NN	O
of  	of  	 IN	O
literature  	literature  	 NN	O
dedicated  	dedicated  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
positive  	positive  	 JJ	B-NP
effects  	effects  	 NNS	I-NP
of  	of  	 IN	I-NP
peripheral  	peripheral  	 JJ	I-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
on  	on  	 IN	O
surrogate  	surrogate  	 JJ	O
endpoints  	endpoints  	 JJ	O
such  	such  	 JJ	O
as  	as  	 IN	O
cholesterol  	cholesterol  	 NN	B-NP
levels  	levels  	 NNS	I-NP
and  	and  	 CC	O
tolerability 	tolerability 	 NN	B-NP
.  	.  	 .	O
In  	In  	 IN	O
light  	light  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
ALLHAT 	ALLHAT 	 NNP	B-NP
,  	,  	 ,	O
we  	we  	 PRP	O
performed  	performed  	 VBD	O
a  	a  	 DT	O
review  	review  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
literature  	literature  	 NN	O
on  	on  	 IN	O
doxazosin 	doxazosin 	 NN	B-NP
,  	,  	 ,	O
terazosin 	terazosin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
prazosin 	prazosin 	 NN	B-NP
.  	.  	 .	O
Methods  	Methods  	 NNP	O
Medline  	Medline  	 NNP	B-NP
and  	and  	 CC	O
the  	the  	 DT	O
Cochrane  	Cochrane  	 JJ	O
databases  	databases  	 NN	O
were  	were  	 VBD	O
used  	used  	 VBN	O
to  	to  	 TO	O
identify  	identify  	 VB	O
English-language  	English-language  	 JJ	B-NP
papers  	papers  	 NNS	I-NP
on  	on  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
in  	in  	 IN	O
studies  	studies  	 NNS	O
targeting  	targeting  	 VBG	O
cardiovascular  	cardiovascular  	 JJ	B-NP
endpoints 	endpoints 	 NN	I-NP
,  	,  	 ,	O
background  	background  	 NN	B-NP
physiologic  	physiologic  	 NN	I-NP
literature 	literature 	 NN	I-NP
,  	,  	 ,	O
or  	or  	 CC	O
any  	any  	 DT	O
studies  	studies  	 NNS	O
suggesting  	suggesting  	 VBG	B-NP
mechanisms  	mechanisms  	 NNS	I-NP
leading  	leading  	 VBG	O
to  	to  	 TO	O
an  	an  	 DT	O
inferior  	inferior  	 JJ	O
performance  	performance  	 NN	O
in  	in  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
endpoints 	endpoints 	 NN	I-NP
.  	.  	 .	O
Medline  	Medline  	 NNP	B-NP
was  	was  	 VBD	O
searched  	searched  	 VBN	O
from  	from  	 IN	O
1966  	1966  	 CD	O
to  	to  	 TO	O
the  	the  	 DT	O
present  	present  	 JJ	O
with  	with  	 IN	O
the  	the  	 DT	O
key  	key  	 JJ	B-NP
words  	words  	 NNS	I-NP
"doxazosin 	"doxazosin 	 RB	O
, 	, 	 ,	O
"  	"  	 ''	O
"prazosin 	"prazosin 	 NNP	O
, 	, 	 ,	O
"  	"  	 ''	O
"terazosin 	"terazosin 	 NNP	O
, 	, 	 ,	O
"  	"  	 ''	O
"adrenergic  	"adrenergic  	 NNP	O
alpha-antagonists 	alpha-antagonists 	 NNP	O
, 	, 	 ,	O
"  	"  	 ''	O
or  	or  	 CC	O
"alpha  	"alpha  	 CD	O
blocker 	blocker 	 NN	O
. 	. 	 .	O
"  	"  	 ''	O
The  	The  	 DT	O
search  	search  	 NN	O
was  	was  	 VBD	O
then  	then  	 RB	O
limited  	limited  	 VBN	O
to  	to  	 TO	O
clinical  	clinical  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
that  	that  	 WDT	O
had  	had  	 VBD	O
"hypertension 	"hypertension 	 NNP	O
"  	"  	 ''	O
as  	as  	 IN	O
a  	a  	 DT	O
key  	key  	 JJ	B-NP
word 	word 	 NN	I-NP
.  	.  	 .	O
Studies  	Studies  	 NNS	O
were  	were  	 VBD	O
included  	included  	 VBN	O
in  	in  	 IN	O
our  	our  	 PRP$	O
review  	review  	 NN	O
if  	if  	 IN	O
they  	they  	 PRP	O
addressed  	addressed  	 VBD	O
either  	either  	 RB	O
one  	one  	 CD	O
or  	or  	 CC	O
a  	a  	 DT	O
combination  	combination  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
three  	three  	 CD	O
agents  	agents  	 NNS	O
as  	as  	 IN	O
the  	the  	 DT	O
main  	main  	 JJ	O
focus  	focus  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
context  	context  	 NN	O
of  	of  	 IN	O
hypertension  	hypertension  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
and  	and  	 CC	O
if  	if  	 IN	O
they  	they  	 PRP	O
in  	in  	 IN	O
some  	some  	 DT	O
way  	way  	 NN	O
addressed  	addressed  	 VBD	O
the  	the  	 DT	O
outcomes  	outcomes  	 NN	O
of  	of  	 IN	O
interest  	interest  	 NN	O
noted  	noted  	 VBD	O
above 	above 	 RB	O
.  	.  	 .	O
Relevant  	Relevant  	 JJ	O
data  	data  	 NNS	O
from  	from  	 IN	O
these  	these  	 DT	O
studies  	studies  	 NNS	O
are  	are  	 VBP	O
reported  	reported  	 VBN	O
descriptively 	descriptively 	 NN	O
.  	.  	 .	O
Other  	Other  	 JJ	O
relevant  	relevant  	 JJ	O
references  	references  	 NNS	O
were  	were  	 VBD	O
acquired  	acquired  	 VBN	O
from  	from  	 IN	O
bibliographic  	bibliographic  	 JJ	B-NP
searches 	searches 	 NNS	I-NP
.  	.  	 .	O
Results  	Results  	 NNS	O
Use  	Use  	 NN	O
in  	in  	 IN	O
Hypertension  	Hypertension  	 NNP	O
and  	and  	 CC	O
Prostatism  	Prostatism  	 NNP	B-NP
Evidence  	Evidence  	 NNP	I-NP
suggests  	suggests  	 VBZ	O
that  	that  	 IN	O
alpha-1  	alpha-1  	 CD	B-NP
antagonists  	antagonists  	 NNS	I-NP
are  	are  	 VBP	O
frequently  	frequently  	 RB	O
prescribed  	prescribed  	 VBN	O
for  	for  	 IN	O
hypertension 	hypertension 	 NN	O
,  	,  	 ,	O
but  	but  	 CC	O
there  	there  	 EX	O
are  	are  	 VBP	O
few  	few  	 JJ	O
published  	published  	 JJ	O
data  	data  	 NNS	O
concerning  	concerning  	 VBG	O
the  	the  	 DT	O
prevalence  	prevalence  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
routine  	routine  	 JJ	B-NP
use  	use  	 NN	I-NP
of  	of  	 IN	I-NP
peripheral  	peripheral  	 JJ	I-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists 	antagonists 	 NNS	I-NP
,  	,  	 ,	O
the  	the  	 DT	O
prevalence  	prevalence  	 NN	O
according  	according  	 VBG	O
to  	to  	 TO	O
co-morbid  	co-morbid  	 JJ	O
conditions  	conditions  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
benign  	benign  	 JJ	B-NP
prostatic  	prostatic  	 JJ	I-NP
hypertrophy  	hypertrophy  	 NN	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
usual  	usual  	 JJ	O
duration  	duration  	 NN	O
of  	of  	 IN	O
therapy 	therapy 	 NN	O
.  	.  	 .	O
In  	In  	 IN	O
the  	the  	 DT	O
sixth  	sixth  	 JJ	O
report  	report  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
Joint  	Joint  	 NNP	O
National  	National  	 NNP	B-NP
Committee  	Committee  	 NNP	I-NP
on  	on  	 IN	O
Prevention 	Prevention 	 NNP	O
,  	,  	 ,	O
Detection 	Detection 	 NNP	O
,  	,  	 ,	O
Evaluation 	Evaluation 	 NNP	O
,  	,  	 ,	O
and  	and  	 CC	O
Treatment  	Treatment  	 NNP	O
of  	of  	 IN	O
High  	High  	 NNP	O
Blood  	Blood  	 NNP	O
Pressure  	Pressure  	 NNP	O
( 	( 	 -LRB-	O
JNC  	JNC  	 NNP	B-NP
VI 	VI 	 NNP	I-NP
) 	) 	 -RRB-	O
,  	,  	 ,	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
are  	are  	 VBP	O
recommended  	recommended  	 VBN	O
not  	not  	 RB	O
only  	only  	 RB	O
as  	as  	 IN	O
second-line  	second-line  	 JJ	B-NP
anti-hypertensive  	anti-hypertensive  	 JJ	I-NP
therapy  	therapy  	 NN	I-NP
after  	after  	 IN	O
low-dose  	low-dose  	 JJ	B-NP
diuretics  	diuretics  	 NN	I-NP
and  	and  	 CC	O
beta  	beta  	 JJ	B-NP
blockers 	blockers 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
also  	also  	 RB	O
for  	for  	 IN	O
specific  	specific  	 JJ	O
indications  	indications  	 NNS	O
such  	such  	 JJ	O
as  	as  	 IN	O
therapy  	therapy  	 NN	O
in  	in  	 IN	O
men  	men  	 NNS	O
with  	with  	 IN	O
hypertension  	hypertension  	 NN	O
and  	and  	 CC	O
prostatism  	prostatism  	 NNS	B-NP
[  	[  	 -LRB-	O
2  	2  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Alpha-1  	Alpha-1  	 NNP	B-NP
antagonists  	antagonists  	 NNS	I-NP
represent  	represent  	 VBP	O
effective  	effective  	 JJ	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
prostatism 	prostatism 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
fifty  	fifty  	 JJ	O
percent  	percent  	 NN	O
of  	of  	 IN	O
men  	men  	 NNS	O
have  	have  	 VBP	O
histologic  	histologic  	 JJ	B-NP
evidence  	evidence  	 NN	I-NP
of  	of  	 IN	O
BPH  	BPH  	 NNP	B-NP
by  	by  	 IN	O
60  	60  	 CD	O
years  	years  	 NNS	O
of  	of  	 IN	O
age  	age  	 NN	O
[  	[  	 -LRB-	O
3  	3  	 CD	O
4  	4  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
National  	National  	 NNP	B-NP
Ambulatory  	Ambulatory  	 NNP	I-NP
Medical  	Medical  	 NNP	I-NP
Care  	Care  	 NNP	I-NP
Survey  	Survey  	 NNP	I-NP
reported  	reported  	 VBD	O
that  	that  	 IN	O
the  	the  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
people  	people  	 NNS	O
on  	on  	 IN	O
any  	any  	 DT	O
type  	type  	 NN	O
of  	of  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonist  	antagonist  	 NN	I-NP
in  	in  	 IN	O
1995  	1995  	 CD	O
was  	was  	 VBD	O
approximately  	approximately  	 RB	O
6  	6  	 CD	O
to  	to  	 TO	O
7 	7 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
those  	those  	 DT	O
with  	with  	 IN	O
hypertension  	hypertension  	 NN	O
[  	[  	 -LRB-	O
5  	5  	 LS	O
]  	]  	 -RRB-	O
.  	.  	 .	O
About  	About  	 IN	O
80 	80 	 CD	O
%  	%  	 NN	O
of  	of  	 IN	O
surveyed  	surveyed  	 JJ	O
physicians  	physicians  	 NNS	O
would  	would  	 MD	O
choose  	choose  	 VB	O
these  	these  	 DT	O
drugs  	drugs  	 NNS	O
as  	as  	 IN	O
a  	a  	 DT	O
first-line  	first-line  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
agent  	agent  	 NN	I-NP
for  	for  	 IN	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
hypertension  	hypertension  	 NN	O
and  	and  	 CC	O
symptoms  	symptoms  	 NNS	B-NP
of  	of  	 IN	O
BPH  	BPH  	 NNP	B-NP
[  	[  	 -LRB-	O
6  	6  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Weight  	Weight  	 NN	O
and  	and  	 CC	O
Fluid  	Fluid  	 NNP	B-NP
Status  	Status  	 NNP	I-NP
Peripheral  	Peripheral  	 NNP	I-NP
alpha-1  	alpha-1  	 NNP	I-NP
antagonists  	antagonists  	 NNS	I-NP
were  	were  	 VBD	O
consistently  	consistently  	 RB	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
fluid  	fluid  	 JJ	B-NP
retention 	retention 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
1984  	1984  	 CD	O
study  	study  	 NN	O
of  	of  	 IN	O
prazosin  	prazosin  	 NN	B-NP
reported  	reported  	 VBD	O
by  	by  	 IN	O
Bauer  	Bauer  	 NNP	O
revealed  	revealed  	 VBD	B-NP
increases  	increases  	 NNS	I-NP
in  	in  	 IN	O
plasma  	plasma  	 JJ	B-NP
volume 	volume 	 NN	I-NP
,  	,  	 ,	O
interstitial  	interstitial  	 JJ	B-NP
fluid  	fluid  	 JJ	I-NP
volume 	volume 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
extracellular  	extracellular  	 JJ	B-NP
fluid  	fluid  	 JJ	I-NP
volume  	volume  	 NN	I-NP
following  	following  	 VBG	O
both  	both  	 DT	O
short-term  	short-term  	 JJ	O
and  	and  	 CC	O
long-term  	long-term  	 JJ	O
therapy  	therapy  	 NN	O
[  	[  	 -LRB-	O
7  	7  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
this  	this  	 DT	O
study  	study  	 NN	O
of  	of  	 IN	O
14  	14  	 CD	O
hypertensive  	hypertensive  	 CD	B-NP
men 	men 	 NNS	I-NP
,  	,  	 ,	O
there  	there  	 EX	O
was  	was  	 VBD	O
a  	a  	 DT	O
significant  	significant  	 JJ	O
1.4  	1.4  	 CD	O
L  	L  	 NNP	O
average  	average  	 JJ	O
increase  	increase  	 NN	O
in  	in  	 IN	O
ECFV 	ECFV 	 NNP	B-NP
,  	,  	 ,	O
with  	with  	 IN	O
a  	a  	 DT	O
200  	200  	 CD	O
mL  	mL  	 JJ	B-NP
average  	average  	 JJ	I-NP
increase  	increase  	 NN	I-NP
in  	in  	 IN	O
plasma  	plasma  	 JJ	B-NP
volume  	volume  	 NN	I-NP
( 	( 	 -LRB-	O
measured  	measured  	 VBN	O
with  	with  	 IN	O
radioisotopic  	radioisotopic  	 JJ	B-NP
assays 	assays 	 NN	I-NP
)  	)  	 -RRB-	O
that  	that  	 WDT	O
occurred  	occurred  	 VBD	O
within  	within  	 IN	O
3-6  	3-6  	 CD	O
weeks  	weeks  	 NNS	O
of  	of  	 IN	O
initiation 	initiation 	 NN	O
,  	,  	 ,	O
lasted  	lasted  	 VBD	O
during  	during  	 IN	O
5  	5  	 CD	O
to  	to  	 TO	O
6  	6  	 CD	O
months  	months  	 NNS	O
of  	of  	 IN	O
chronic  	chronic  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
was  	was  	 VBD	O
still  	still  	 RB	O
present  	present  	 VB	O
during  	during  	 IN	O
a  	a  	 DT	O
two-week  	two-week  	 JJ	B-NP
washout  	washout  	 JJ	I-NP
period 	period 	 NN	I-NP
.  	.  	 .	O
There  	There  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
weight  	weight  	 NN	B-NP
change  	change  	 NN	I-NP
in  	in  	 IN	O
that  	that  	 DT	O
study 	study 	 NN	O
,  	,  	 ,	O
but  	but  	 CC	O
two  	two  	 CD	O
other  	other  	 JJ	O
studies  	studies  	 NNS	O
demonstrated  	demonstrated  	 VBD	O
both  	both  	 PDT	O
an  	an  	 DT	O
increase  	increase  	 NN	O
in  	in  	 IN	O
weight  	weight  	 NN	O
as  	as  	 IN	O
well  	well  	 RB	O
as  	as  	 IN	O
laboratory  	laboratory  	 NN	B-NP
changes  	changes  	 NNS	I-NP
consistent  	consistent  	 JJ	O
with  	with  	 IN	O
volume  	volume  	 NN	B-NP
expansion  	expansion  	 NN	I-NP
for  	for  	 IN	I-NP
prazosin  	prazosin  	 NNS	I-NP
[  	[  	 -LRB-	O
8  	8  	 CD	O
9  	9  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Bauer  	Bauer  	 NNP	O
and  	and  	 CC	O
his  	his  	 PRP$	O
colleagues  	colleagues  	 NNS	O
suggested  	suggested  	 VBD	O
that  	that  	 IN	O
a  	a  	 DT	O
net  	net  	 JJ	O
increase  	increase  	 NN	O
in  	in  	 IN	O
total  	total  	 JJ	B-NP
body  	body  	 NN	I-NP
sodium  	sodium  	 NN	I-NP
from  	from  	 IN	O
an  	an  	 DT	O
acute  	acute  	 JJ	B-NP
renal  	renal  	 JJ	I-NP
effect  	effect  	 NN	I-NP
of  	of  	 IN	I-NP
prazosin  	prazosin  	 NN	I-NP
was  	was  	 VBD	O
offset  	offset  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
decrease  	decrease  	 NN	O
in  	in  	 IN	O
actual  	actual  	 JJ	O
body  	body  	 NN	O
weight 	weight 	 NN	O
.  	.  	 .	O
They  	They  	 PRP	O
also  	also  	 RB	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
fractional  	fractional  	 JJ	B-NP
excretion  	excretion  	 NN	I-NP
of  	of  	 IN	I-NP
sodium  	sodium  	 NN	I-NP
was  	was  	 VBD	O
unchanged  	unchanged  	 JJ	O
during  	during  	 IN	O
treatment 	treatment 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
further  	further  	 RB	O
suggested  	suggested  	 VBN	O
that  	that  	 IN	O
the  	the  	 DT	O
acute  	acute  	 JJ	B-NP
changes  	changes  	 NNS	I-NP
were  	were  	 VBD	O
followed  	followed  	 VBN	O
by  	by  	 IN	O
chronic  	chronic  	 JJ	B-NP
sodium  	sodium  	 NN	I-NP
homeostasis  	homeostasis  	 NNS	I-NP
and  	and  	 CC	O
maintenance  	maintenance  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
increased  	increased  	 JJ	O
total  	total  	 JJ	B-NP
body  	body  	 NN	I-NP
sodium 	sodium 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
VA  	VA  	 NNP	B-NP
Cooperative  	Cooperative  	 NNP	I-NP
Study  	Study  	 NNP	I-NP
on  	on  	 IN	O
Antihypertensive  	Antihypertensive  	 NNP	B-NP
agents  	agents  	 NNS	I-NP
was  	was  	 VBD	O
a  	a  	 DT	O
double-blind 	double-blind 	 JJ	B-NP
,  	,  	 ,	O
randomized  	randomized  	 VBD	O
controlled  	controlled  	 VBN	B-NP
trial  	trial  	 NN	I-NP
comparing  	comparing  	 VBG	I-NP
atenolol 	atenolol 	 NN	I-NP
,  	,  	 ,	O
captopril 	captopril 	 NN	B-NP
,  	,  	 ,	O
clonidine 	clonidine 	 NN	B-NP
,  	,  	 ,	O
diltiazem 	diltiazem 	 NN	B-NP
,  	,  	 ,	O
hydrochlorothiazide 	hydrochlorothiazide 	 NN	B-NP
,  	,  	 ,	O
prazosin 	prazosin 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
placebo  	placebo  	 NN	O
for  	for  	 IN	O
differences  	differences  	 NNS	O
in  	in  	 IN	O
antihypertensive  	antihypertensive  	 JJ	B-NP
efficacy  	efficacy  	 NN	I-NP
in  	in  	 IN	O
1,105  	1,105  	 CD	O
men  	men  	 NNS	O
who  	who  	 WP	O
had  	had  	 VBD	O
mild  	mild  	 JJ	O
diastolic  	diastolic  	 JJ	B-NP
hypertension  	hypertension  	 NN	I-NP
[  	[  	 -LRB-	O
10  	10  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
A  	A  	 DT	O
highly  	highly  	 RB	O
significant  	significant  	 JJ	O
weight  	weight  	 NN	B-NP
gain  	gain  	 NN	I-NP
of  	of  	 IN	O
1  	1  	 CD	O
kilogram  	kilogram  	 NNS	O
was  	was  	 VBD	O
observed  	observed  	 VBN	O
at  	at  	 IN	O
8  	8  	 CD	O
weeks  	weeks  	 NNS	O
with  	with  	 IN	O
prazosin  	prazosin  	 VBG	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
baseline  	baseline  	 VB	O
( 	( 	 -LRB-	O
p  	p  	 FW	O
< 	< 	 SYM	O
.001 	.001 	 FW	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
this  	this  	 DT	O
gain  	gain  	 NN	O
was  	was  	 VBD	O
also  	also  	 RB	O
statistically  	statistically  	 RB	O
significant  	significant  	 JJ	O
when  	when  	 WRB	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
8-week  	8-week  	 JJ	O
weight  	weight  	 NN	O
changes  	changes  	 NNS	O
in  	in  	 IN	O
all  	all  	 DT	O
other  	other  	 JJ	O
groups  	groups  	 NNS	O
that  	that  	 WDT	O
had  	had  	 VBD	O
experienced  	experienced  	 VBN	O
either  	either  	 DT	O
weight  	weight  	 NN	B-NP
loss  	loss  	 NN	I-NP
or  	or  	 CC	O
no  	no  	 DT	O
mean  	mean  	 JJ	B-NP
weight  	weight  	 NN	I-NP
change  	change  	 NN	I-NP
( 	( 	 -LRB-	O
p  	p  	 CD	O
< 	< 	 SYM	O
0.05 	0.05 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
prazosin  	prazosin  	 JJ	B-NP
arm  	arm  	 NN	I-NP
had  	had  	 VBD	O
the  	the  	 DT	O
highest  	highest  	 JJS	O
rate  	rate  	 NN	O
of  	of  	 IN	O
adverse  	adverse  	 JJ	O
effects 	effects 	 NNS	O
,  	,  	 ,	O
leading  	leading  	 VBG	O
to  	to  	 TO	O
discontinuation  	discontinuation  	 VB	O
of  	of  	 IN	O
treatment 	treatment 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
termination  	termination  	 NN	B-NP
rate  	rate  	 NN	I-NP
of  	of  	 IN	O
13.8 	13.8 	 CD	O
%  	%  	 NN	O
was  	was  	 VBD	O
higher  	higher  	 JJR	O
than  	than  	 IN	O
the  	the  	 DT	O
termination  	termination  	 NN	B-NP
rate  	rate  	 NN	I-NP
from  	from  	 IN	O
adverse  	adverse  	 JJ	O
effects  	effects  	 NNS	O
for  	for  	 IN	O
clonidine  	clonidine  	 NNS	B-NP
( 	( 	 -LRB-	O
10.1 	10.1 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
significantly  	significantly  	 RB	O
higher  	higher  	 JJR	O
than  	than  	 IN	O
the  	the  	 DT	O
rates  	rates  	 NNS	O
for  	for  	 IN	O
captopril  	captopril  	 NNS	B-NP
( 	( 	 -LRB-	O
4.8 	4.8 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
atenolol  	atenolol  	 NNS	B-NP
( 	( 	 -LRB-	O
2.2 	2.2 	 CD	O
% 	% 	 NN	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
or  	or  	 CC	O
hydrochlorothiazide  	hydrochlorothiazide  	 NNS	B-NP
( 	( 	 -LRB-	O
1.1 	1.1 	 CD	O
% 	% 	 NN	O
)  	)  	 -RRB-	O
[  	[  	 -LRB-	O
11  	11  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
number  	number  	 NN	O
of  	of  	 IN	O
men  	men  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
prazosin  	prazosin  	 JJ	B-NP
decreased  	decreased  	 NN	I-NP
from  	from  	 IN	O
62  	62  	 CD	O
at  	at  	 IN	O
the  	the  	 DT	O
beginning  	beginning  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
trial  	trial  	 NN	O
to  	to  	 TO	O
28  	28  	 CD	O
by  	by  	 IN	O
the  	the  	 DT	O
end 	end 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
average  	average  	 JJ	O
weight  	weight  	 NN	B-NP
gain  	gain  	 NN	I-NP
of  	of  	 IN	O
0.5  	0.5  	 CD	O
kilograms  	kilograms  	 NNS	O
from  	from  	 IN	O
baseline  	baseline  	 NN	B-NP
was  	was  	 VBD	O
no  	no  	 DT	O
longer  	longer  	 RBR	O
statistically  	statistically  	 JJ	O
significant  	significant  	 JJ	O
at  	at  	 IN	O
one  	one  	 CD	O
year  	year  	 NN	O
of  	of  	 IN	O
therapy  	therapy  	 NN	O
when  	when  	 WRB	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
original  	original  	 JJ	B-NP
baseline  	baseline  	 NN	I-NP
weight  	weight  	 NN	I-NP
or  	or  	 CC	O
the  	the  	 DT	O
other  	other  	 JJ	O
therapies 	therapies 	 NNS	O
.  	.  	 .	O
Safety  	Safety  	 NNP	O
and  	and  	 CC	O
tolerability  	tolerability  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
with  	with  	 IN	O
terazosin  	terazosin  	 NNS	B-NP
have  	have  	 VBP	O
shown  	shown  	 VBN	O
similar  	similar  	 JJ	O
results  	results  	 NNS	O
( 	( 	 -LRB-	O
Table  	Table  	 NNP	O
1 	1 	 CD	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Patients  	Patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
terazosin  	terazosin  	 NN	B-NP
tended  	tended  	 VBD	O
to  	to  	 TO	O
gain  	gain  	 VB	O
about  	about  	 IN	O
1  	1  	 CD	O
kilogram  	kilogram  	 NN	O
from  	from  	 IN	O
baseline  	baseline  	 NN	B-NP
on  	on  	 IN	O
active  	active  	 JJ	O
therapy  	therapy  	 NN	O
during  	during  	 IN	O
these  	these  	 DT	O
trials 	trials 	 NNS	O
,  	,  	 ,	O
and  	and  	 CC	O
those  	those  	 DT	O
on  	on  	 IN	O
placebo  	placebo  	 JJ	O
therapy  	therapy  	 NN	O
lost  	lost  	 VBD	O
weight 	weight 	 NN	O
.  	.  	 .	O
Two  	Two  	 CD	O
of  	of  	 IN	O
the  	the  	 DT	O
randomized  	randomized  	 JJ	B-NP
trials  	trials  	 NNS	I-NP
included  	included  	 VBD	O
a  	a  	 DT	O
phase  	phase  	 NN	O
for  	for  	 IN	O
withdrawal  	withdrawal  	 NN	B-NP
from  	from  	 IN	O
active  	active  	 JJ	O
therapy 	therapy 	 NN	O
,  	,  	 ,	O
with  	with  	 IN	O
weight  	weight  	 NN	B-NP
information  	information  	 NN	I-NP
reported  	reported  	 VBD	O
by  	by  	 IN	O
Ruoff  	Ruoff  	 NNP	O
[  	[  	 -LRB-	O
12  	12  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Withdrawal  	Withdrawal  	 NN	B-NP
from  	from  	 IN	O
active  	active  	 JJ	O
therapy  	therapy  	 NN	O
was  	was  	 VBD	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
loss  	loss  	 NN	O
of  	of  	 IN	O
1.3  	1.3  	 CD	O
kilograms 	kilograms 	 NNS	O
.  	.  	 .	O
Doxazosin  	Doxazosin  	 NNP	B-NP
has  	has  	 VBZ	O
also  	also  	 RB	O
been  	been  	 VBN	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
volume  	volume  	 NN	B-NP
expansion 	expansion 	 NN	I-NP
.  	.  	 .	O
A  	A  	 DT	O
physiology  	physiology  	 JJ	B-NP
study  	study  	 NN	I-NP
reported  	reported  	 VBD	O
by  	by  	 IN	O
Lund-Johansen  	Lund-Johansen  	 NNP	B-NP
demonstrated  	demonstrated  	 VBD	O
a  	a  	 DT	O
plasma  	plasma  	 JJ	B-NP
volume  	volume  	 NN	I-NP
fluid  	fluid  	 NN	I-NP
expansion  	expansion  	 NN	I-NP
of  	of  	 IN	O
about  	about  	 IN	O
10 	10 	 CD	O
%  	%  	 NN	O
when  	when  	 WRB	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
baseline  	baseline  	 VB	O
values  	values  	 NNS	O
[  	[  	 -LRB-	O
13  	13  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Larger  	Larger  	 JJR	O
randomized  	randomized  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trials  	trials  	 NNS	I-NP
have  	have  	 VBP	O
also  	also  	 RB	O
consistently  	consistently  	 RB	O
demonstrated  	demonstrated  	 VBN	O
that  	that  	 IN	O
patients  	patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
gain  	gain  	 NN	I-NP
weight 	weight 	 NN	I-NP
,  	,  	 ,	O
as  	as  	 IN	O
summarized  	summarized  	 NN	O
in  	in  	 IN	O
Table  	Table  	 NNP	O
2 	2 	 CD	O
.  	.  	 .	O
While  	While  	 IN	O
patients  	patients  	 NNS	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
doxazosin  	doxazosin  	 NNS	B-NP
tend  	tend  	 VBP	O
to  	to  	 TO	O
gain  	gain  	 VB	O
weight 	weight 	 NN	O
,  	,  	 ,	O
patients  	patients  	 NNS	O
on  	on  	 IN	O
placebo  	placebo  	 JJ	O
therapy  	therapy  	 NN	O
lost  	lost  	 VBD	O
weight 	weight 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
Treatment  	Treatment  	 NNP	B-NP
of  	of  	 IN	I-NP
Mild  	Mild  	 NNP	I-NP
Hypertension  	Hypertension  	 NNP	I-NP
Study  	Study  	 NNP	I-NP
( 	( 	 -LRB-	O
TOMHS 	TOMHS 	 NNP	B-NP
)  	)  	 -RRB-	O
trial  	trial  	 NN	O
is  	is  	 VBZ	O
a  	a  	 DT	O
notable  	notable  	 JJ	O
exception  	exception  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
trend  	trend  	 NN	O
towards  	towards  	 IN	O
weight  	weight  	 NN	B-NP
gain  	gain  	 NN	I-NP
[  	[  	 -LRB-	O
14  	14  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
All  	All  	 DT	O
five  	five  	 CD	O
treatment  	treatment  	 NN	B-NP
groups  	groups  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
placebo  	placebo  	 JJ	O
group  	group  	 NN	O
received  	received  	 VBD	O
intensive  	intensive  	 JJ	B-NP
dietary  	dietary  	 JJ	I-NP
counseling  	counseling  	 NN	I-NP
aimed  	aimed  	 VBN	O
at  	at  	 IN	O
weight  	weight  	 NN	B-NP
loss 	loss 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
all  	all  	 DT	O
groups  	groups  	 NNS	O
lost  	lost  	 VBD	O
weight  	weight  	 NN	O
without  	without  	 IN	O
significant  	significant  	 JJ	O
differences  	differences  	 NNS	O
between  	between  	 IN	O
trial  	trial  	 NN	B-NP
arms 	arms 	 NNS	I-NP
.  	.  	 .	O
Neurohormonal  	Neurohormonal  	 NNP	B-NP
and  	and  	 CC	O
Cellular  	Cellular  	 NNP	B-NP
Effects  	Effects  	 NNPS	I-NP
Physiologic  	Physiologic  	 NNP	I-NP
studies  	studies  	 NNS	I-NP
with  	with  	 IN	O
small  	small  	 JJ	O
numbers  	numbers  	 NNS	O
of  	of  	 IN	O
participants  	participants  	 NNS	B-NP
are  	are  	 VBP	O
by  	by  	 IN	O
nature  	nature  	 NN	O
underpowered  	underpowered  	 NN	O
to  	to  	 TO	O
detect  	detect  	 VB	O
meaningful  	meaningful  	 JJ	O
population  	population  	 NN	B-NP
differences 	differences 	 NNS	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
may  	may  	 MD	O
provide  	provide  	 VB	O
a  	a  	 DT	O
starting  	starting  	 VBG	B-NP
point  	point  	 NN	I-NP
when  	when  	 WRB	O
such  	such  	 JJ	O
data  	data  	 NNS	O
are  	are  	 VBP	O
not  	not  	 RB	O
available 	available 	 JJ	O
.  	.  	 .	O
Peripheral  	Peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
were  	were  	 VBD	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
perturbations  	perturbations  	 NN	B-NP
in  	in  	 IN	O
neurohormonal  	neurohormonal  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
in  	in  	 IN	O
various  	various  	 JJ	O
studies 	studies 	 NNS	O
.  	.  	 .	O
In  	In  	 IN	O
particular 	particular 	 JJ	O
,  	,  	 ,	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
an  	an  	 DT	O
increase  	increase  	 NN	O
in  	in  	 IN	O
plasma  	plasma  	 JJ	B-NP
norepinephrine  	norepinephrine  	 NN	I-NP
in  	in  	 IN	O
diverse  	diverse  	 JJ	B-NP
patient  	patient  	 NN	I-NP
populations 	populations 	 NNS	I-NP
,  	,  	 ,	O
as  	as  	 IN	O
summarized  	summarized  	 NN	O
in  	in  	 IN	O
Table  	Table  	 NNP	O
3 	3 	 CD	O
.  	.  	 .	O
This  	This  	 DT	O
table  	table  	 NN	O
reflects  	reflects  	 VBZ	O
increases  	increases  	 NNS	O
in  	in  	 IN	O
norepinephrine  	norepinephrine  	 NN	B-NP
in  	in  	 IN	O
normotensive  	normotensive  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
,  	,  	 ,	O
hypertensive  	hypertensive  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
patients  	patients  	 NNS	O
with  	with  	 IN	O
chronic  	chronic  	 JJ	B-NP
congestive  	congestive  	 JJ	I-NP
heart  	heart  	 NN	I-NP
failure  	failure  	 NN	I-NP
from  	from  	 IN	O
a  	a  	 DT	O
variety  	variety  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
small  	small  	 JJ	O
studies 	studies 	 NNS	O
.  	.  	 .	O
Several  	Several  	 JJ	O
lines  	lines  	 NNS	O
of  	of  	 IN	O
evidence  	evidence  	 NN	O
suggest  	suggest  	 VBP	O
that  	that  	 IN	O
elevated  	elevated  	 JJ	O
catecholamine  	catecholamine  	 JJ	B-NP
levels  	levels  	 NNS	I-NP
are  	are  	 VBP	O
cardiotoxic  	cardiotoxic  	 NNS	B-NP
[  	[  	 -LRB-	O
15  	15  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Elevated  	Elevated  	 JJ	B-NP
plasma  	plasma  	 JJ	I-NP
norepinephrine  	norepinephrine  	 JJ	I-NP
levels  	levels  	 NNS	I-NP
are  	are  	 VBP	O
hypothesized  	hypothesized  	 VBN	O
to  	to  	 TO	O
cause  	cause  	 VB	O
direct  	direct  	 JJ	O
myocardial  	myocardial  	 JJ	B-NP
damage  	damage  	 NN	I-NP
through  	through  	 IN	O
many  	many  	 JJ	O
mechanisms 	mechanisms 	 NNS	O
,  	,  	 ,	O
which  	which  	 WDT	O
may  	may  	 MD	O
be  	be  	 VB	O
amplified  	amplified  	 VBN	O
by  	by  	 IN	O
concomitant  	concomitant  	 CD	B-NP
alpha-1  	alpha-1  	 CD	I-NP
blockade 	blockade 	 NN	I-NP
.  	.  	 .	O
In  	In  	 IN	O
rats 	rats 	 NNS	O
,  	,  	 ,	O
norepinephrine  	norepinephrine  	 FW	B-NP
stimulates  	stimulates  	 FW	O
apoptosis 	apoptosis 	 FW	B-NP
,  	,  	 ,	O
which  	which  	 WDT	O
is  	is  	 VBZ	O
mediated  	mediated  	 VBN	O
through  	through  	 IN	O
beta  	beta  	 JJ	B-NP
receptors  	receptors  	 NNS	I-NP
[  	[  	 -LRB-	O
16  	16  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
addition 	addition 	 NN	B-NP
,  	,  	 ,	O
alpha-1  	alpha-1  	 CD	B-NP
cardiac  	cardiac  	 JJ	I-NP
receptors  	receptors  	 NNS	I-NP
inhibit  	inhibit  	 VBP	O
this  	this  	 DT	O
response  	response  	 NN	O
in  	in  	 IN	O
rat  	rat  	 JJ	B-NP
myocytes  	myocytes  	 NNS	I-NP
[  	[  	 -LRB-	O
17  	17  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
increased  	increased  	 JJ	O
concentration  	concentration  	 NN	B-NP
of  	of  	 IN	I-NP
norepinephrine  	norepinephrine  	 NNS	I-NP
leading  	leading  	 VBG	O
to  	to  	 TO	O
cardiac  	cardiac  	 VB	O
beta  	beta  	 JJ	B-NP
receptor  	receptor  	 NN	I-NP
stimulation  	stimulation  	 VBZ	I-NP
combined  	combined  	 VBN	O
with  	with  	 IN	O
alpha-1  	alpha-1  	 CD	B-NP
receptor  	receptor  	 NN	I-NP
inhibition  	inhibition  	 NNS	I-NP
may  	may  	 MD	O
lead  	lead  	 VB	O
to  	to  	 TO	O
increased  	increased  	 JJ	O
apoptosis  	apoptosis  	 NN	B-NP
in  	in  	 IN	O
myocytes 	myocytes 	 NN	B-NP
.  	.  	 .	O
Other  	Other  	 JJ	O
hormones  	hormones  	 NNS	O
that  	that  	 WDT	O
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
disease  	disease  	 NN	I-NP
are  	are  	 VBP	O
affected  	affected  	 VBN	O
by  	by  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists 	antagonists 	 NNS	I-NP
.  	.  	 .	O
Endothelin-1  	Endothelin-1  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
vascular  	vascular  	 JJ	B-NP
hormone 	hormone 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
may  	may  	 MD	O
play  	play  	 VB	O
a  	a  	 DT	O
role  	role  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
generation  	generation  	 NN	O
and  	and  	 CC	O
maintenance  	maintenance  	 NN	O
of  	of  	 IN	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
[  	[  	 -LRB-	O
18  	18  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
In  	In  	 IN	O
hypertensive  	hypertensive  	 JJ	B-NP
patients 	patients 	 NNS	I-NP
,  	,  	 ,	O
doxazosin  	doxazosin  	 NN	B-NP
lowers  	lowers  	 VBZ	O
von  	von  	 NNP	B-NP
Willebrand  	Willebrand  	 NNP	I-NP
factor  	factor  	 NN	I-NP
commensurate  	commensurate  	 NN	O
with  	with  	 IN	O
blood  	blood  	 NN	O
pressure 	pressure 	 NN	O
,  	,  	 ,	O
but  	but  	 CC	O
it  	it  	 PRP	O
does  	does  	 VBZ	O
not  	not  	 RB	O
lower  	lower  	 RBR	O
high  	high  	 JJ	O
levels  	levels  	 NNS	O
of  	of  	 IN	O
endothelin-1  	endothelin-1  	 CD	B-NP
while  	while  	 IN	O
atenolol  	atenolol  	 NN	B-NP
does  	does  	 VBZ	O
[  	[  	 -LRB-	O
19  	19  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Other  	Other  	 JJ	O
mechanisms  	mechanisms  	 NNS	O
for  	for  	 IN	O
cellular  	cellular  	 JJ	B-NP
injury  	injury  	 NNS	I-NP
have  	have  	 VBP	O
been  	been  	 VBN	O
suggested 	suggested 	 VBN	O
.  	.  	 .	O
Hooper  	Hooper  	 RB	O
proposed  	proposed  	 VBN	O
that  	that  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
alter  	alter  	 VBP	O
cellular  	cellular  	 JJ	B-NP
repair  	repair  	 NN	I-NP
mechanisms 	mechanisms 	 NNS	I-NP
,  	,  	 ,	O
possibly  	possibly  	 RB	O
causing  	causing  	 VBG	O
cardiac  	cardiac  	 JJ	B-NP
damage 	damage 	 NN	I-NP
.  	.  	 .	O
He  	He  	 PRP	O
noted  	noted  	 VBD	O
that  	that  	 DT	O
prazosin  	prazosin  	 JJ	B-NP
blocks  	blocks  	 NNS	I-NP
heat  	heat  	 NN	I-NP
shock  	shock  	 NN	I-NP
protein  	protein  	 NN	I-NP
expression  	expression  	 NN	I-NP
in  	in  	 IN	O
myocardium 	myocardium 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
it  	it  	 PRP	O
has  	has  	 VBZ	O
been  	been  	 VBN	O
hypothesized  	hypothesized  	 VBN	O
that  	that  	 IN	O
this  	this  	 DT	O
may  	may  	 MD	O
leave  	leave  	 VB	O
myocardium  	myocardium  	 VBN	O
more  	more  	 RBR	O
vulnerable  	vulnerable  	 JJ	O
to  	to  	 TO	O
injury  	injury  	 VB	O
[  	[  	 -LRB-	O
20  	20  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Epidemiological  	Epidemiological  	 NNP	B-NP
and  	and  	 CC	O
Clinical  	Clinical  	 NNP	B-NP
Trial  	Trial  	 NNP	I-NP
Data  	Data  	 NNP	I-NP
Between  	Between  	 IN	O
1966  	1966  	 CD	O
and  	and  	 CC	O
2001 	2001 	 CD	O
,  	,  	 ,	O
there  	there  	 EX	O
were  	were  	 VBD	O
188  	188  	 CD	O
published  	published  	 VBN	O
cardiovascular  	cardiovascular  	 JJ	O
randomized  	randomized  	 NNS	O
controlled  	controlled  	 VBN	B-NP
trials  	trials  	 NNS	I-NP
related  	related  	 VBN	O
to  	to  	 TO	O
the  	the  	 DT	O
treatment  	treatment  	 NN	O
of  	of  	 IN	O
hypertension  	hypertension  	 NN	O
with  	with  	 IN	O
the  	the  	 DT	O
use  	use  	 NN	O
of  	of  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists 	antagonists 	 NNS	I-NP
.  	.  	 .	O
Among  	Among  	 IN	O
these 	these 	 DT	O
,  	,  	 ,	O
only  	only  	 RB	O
ALLHAT  	ALLHAT  	 NNP	B-NP
specifically  	specifically  	 RB	O
assessed  	assessed  	 VBN	B-NP
differences  	differences  	 NNS	I-NP
in  	in  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
endpoints  	endpoints  	 NNS	I-NP
resulting  	resulting  	 VBG	O
from  	from  	 IN	O
control  	control  	 NN	O
of  	of  	 IN	O
hypertension  	hypertension  	 NN	O
with  	with  	 IN	O
a  	a  	 DT	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonist 	antagonist 	 NNS	I-NP
.  	.  	 .	O
Most  	Most  	 JJS	O
of  	of  	 IN	O
these  	these  	 DT	O
trials  	trials  	 NNS	O
focused  	focused  	 VBN	O
on  	on  	 IN	O
surrogate  	surrogate  	 JJ	O
endpoints  	endpoints  	 JJ	O
such  	such  	 JJ	O
as  	as  	 IN	O
equivalence  	equivalence  	 NN	O
of  	of  	 IN	O
blood-pressure  	blood-pressure  	 JJ	B-NP
reduction  	reduction  	 NN	I-NP
and  	and  	 CC	O
effects  	effects  	 NNS	O
on  	on  	 IN	O
cholesterol 	cholesterol 	 NN	B-NP
.  	.  	 .	O
Other  	Other  	 JJ	O
studies  	studies  	 NNS	O
focused  	focused  	 VBN	O
on  	on  	 IN	O
tolerability  	tolerability  	 NN	B-NP
and  	and  	 CC	O
pharmacology 	pharmacology 	 NN	O
.  	.  	 .	O
There  	There  	 EX	O
are  	are  	 VBP	O
no  	no  	 DT	O
case  	case  	 NN	B-NP
control 	control 	 NN	I-NP
,  	,  	 ,	O
cohort 	cohort 	 NN	B-NP
,  	,  	 ,	O
or  	or  	 CC	O
other  	other  	 JJ	O
studies  	studies  	 NNS	O
that  	that  	 WDT	O
analyzed  	analyzed  	 VBD	O
the  	the  	 DT	O
impact  	impact  	 NN	O
of  	of  	 IN	O
these  	these  	 DT	O
agents  	agents  	 NNS	O
on  	on  	 IN	O
cardiovascular  	cardiovascular  	 JJ	B-NP
endpoints 	endpoints 	 NN	I-NP
.  	.  	 .	O
Using  	Using  	 VBG	O
data  	data  	 NNS	O
from  	from  	 IN	O
other  	other  	 JJ	O
trials  	trials  	 NNS	O
may  	may  	 MD	O
offer  	offer  	 VB	O
a  	a  	 DT	O
partial  	partial  	 JJ	O
framework  	framework  	 NN	O
for  	for  	 IN	O
the  	the  	 DT	O
interpretation  	interpretation  	 NN	B-NP
of  	of  	 IN	O
newer  	newer  	 JJR	O
findings 	findings 	 NNS	O
.  	.  	 .	O
ALLHAT  	ALLHAT  	 NNP	B-NP
demonstrated  	demonstrated  	 VBD	O
a  	a  	 DT	O
highly  	highly  	 RB	O
statistically  	statistically  	 RB	O
significant 	significant 	 JJ	O
,  	,  	 ,	O
near  	near  	 IN	O
doubling  	doubling  	 VBG	O
in  	in  	 IN	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
arm  	arm  	 NN	I-NP
compared  	compared  	 VBN	O
to  	to  	 TO	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
occurrences  	occurrences  	 NNS	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
chlorthalidone  	chlorthalidone  	 JJ	B-NP
arm 	arm 	 NN	I-NP
.  	.  	 .	O
Although  	Although  	 IN	O
there  	there  	 EX	O
was  	was  	 VBD	O
no  	no  	 DT	O
difference  	difference  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
primary  	primary  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
of  	of  	 IN	I-NP
CHD  	CHD  	 NNP	I-NP
or  	or  	 CC	O
the  	the  	 DT	O
secondary  	secondary  	 JJ	B-NP
outcome  	outcome  	 NN	I-NP
of  	of  	 IN	I-NP
total  	total  	 JJ	I-NP
mortality 	mortality 	 NN	I-NP
,  	,  	 ,	O
there  	there  	 EX	O
were  	were  	 VBD	O
small  	small  	 JJ	O
but  	but  	 CC	O
statistically  	statistically  	 RB	O
significant  	significant  	 JJ	O
increases  	increases  	 NNS	O
in  	in  	 IN	O
the  	the  	 DT	O
secondary  	secondary  	 JJ	B-NP
outcomes  	outcomes  	 NNS	I-NP
of  	of  	 IN	O
angina  	angina  	 NNS	O
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
1.16 	1.16 	 CD	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
1.05-1.27 	1.05-1.27 	 NNP	O
)  	)  	 -RRB-	O
and  	and  	 CC	O
stroke  	stroke  	 NN	O
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
1.19 	1.19 	 CD	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
1.01-1.40 	1.01-1.40 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
Since  	Since  	 IN	O
ALLHAT  	ALLHAT  	 NNP	B-NP
is  	is  	 VBZ	O
a  	a  	 DT	O
comparative  	comparative  	 JJ	B-NP
trial 	trial 	 NN	I-NP
,  	,  	 ,	O
we  	we  	 PRP	O
know  	know  	 VBP	O
that  	that  	 DT	O
doxazosin  	doxazosin  	 NN	B-NP
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
more  	more  	 RBR	O
adverse  	adverse  	 JJ	O
cardiovascular  	cardiovascular  	 JJ	B-NP
outcomes  	outcomes  	 NNS	I-NP
than  	than  	 IN	O
low-dose  	low-dose  	 JJ	B-NP
chlorthalidone 	chlorthalidone 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
we  	we  	 PRP	O
do  	do  	 VBP	O
not  	not  	 RB	O
know  	know  	 VB	O
how  	how  	 WRB	O
doxazosin  	doxazosin  	 NNS	B-NP
might  	might  	 MD	O
compare  	compare  	 VB	O
with  	with  	 IN	O
placebo 	placebo 	 NN	O
.  	.  	 .	O
The  	The  	 DT	O
SHEP  	SHEP  	 NNP	B-NP
trial 	trial 	 NN	I-NP
,  	,  	 ,	O
however 	however 	 RB	O
,  	,  	 ,	O
does  	does  	 VBZ	O
provide  	provide  	 VB	O
a  	a  	 DT	O
comparison  	comparison  	 NN	O
between  	between  	 IN	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
and  	and  	 CC	O
placebo  	placebo  	 JJ	O
therapy  	therapy  	 NN	O
for  	for  	 IN	O
a  	a  	 DT	O
reference  	reference  	 NN	B-NP
point  	point  	 NN	I-NP
of  	of  	 IN	I-NP
heart  	heart  	 NN	I-NP
failure 	failure 	 NN	I-NP
,  	,  	 ,	O
although  	although  	 IN	O
the  	the  	 DT	O
study  	study  	 NN	B-NP
populations  	populations  	 NNS	I-NP
have  	have  	 VBP	O
different  	different  	 JJ	O
demographic  	demographic  	 NN	B-NP
and  	and  	 CC	O
blood  	blood  	 NN	O
pressure  	pressure  	 NN	O
distributions  	distributions  	 NNS	O
[  	[  	 -LRB-	O
21  	21  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
SHEP  	SHEP  	 NNP	B-NP
trial  	trial  	 NN	I-NP
included  	included  	 VBD	O
4,736  	4,736  	 CD	O
people  	people  	 NNS	O
aged  	aged  	 VBN	O
60  	60  	 CD	O
and  	and  	 CC	O
older  	older  	 NNS	O
who  	who  	 WP	O
had  	had  	 VBD	O
a  	a  	 DT	O
systolic  	systolic  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
of  	of  	 IN	O
160  	160  	 CD	O
to  	to  	 TO	O
219  	219  	 CD	O
mmHg  	mmHg  	 JJ	O
and  	and  	 CC	O
a  	a  	 DT	O
diastolic  	diastolic  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
of  	of  	 IN	O
less  	less  	 JJR	O
than  	than  	 IN	O
90  	90  	 CD	O
mmHg 	mmHg 	 NN	B-NP
.  	.  	 .	O
Subjects  	Subjects  	 NNS	B-NP
were  	were  	 VBD	O
randomized  	randomized  	 VBN	O
to  	to  	 TO	O
low-dose  	low-dose  	 JJ	B-NP
diuretics  	diuretics  	 NN	I-NP
or  	or  	 CC	O
placebo 	placebo 	 NN	O
,  	,  	 ,	O
and  	and  	 CC	O
were  	were  	 VBD	O
followed  	followed  	 VBN	O
for  	for  	 IN	O
an  	an  	 DT	O
average  	average  	 NN	O
of  	of  	 IN	O
4.5  	4.5  	 CD	O
years  	years  	 NNS	O
for  	for  	 IN	O
major  	major  	 JJ	O
CV  	CV  	 NN	O
events 	events 	 NNS	O
.  	.  	 .	O
Comparisons  	Comparisons  	 NNS	O
between  	between  	 IN	O
those  	those  	 DT	O
randomized  	randomized  	 NN	O
to  	to  	 TO	O
active  	active  	 JJ	O
therapy  	therapy  	 NN	O
and  	and  	 CC	O
those  	those  	 DT	O
on  	on  	 IN	O
placebo  	placebo  	 NN	O
demonstrated  	demonstrated  	 VBD	O
nearly  	nearly  	 RB	O
a  	a  	 DT	O
50 	50 	 CD	O
%  	%  	 NN	O
reduction  	reduction  	 NN	O
in  	in  	 IN	O
fatal  	fatal  	 JJ	O
and  	and  	 CC	O
nonfatal  	nonfatal  	 JJ	B-NP
heart  	heart  	 NN	I-NP
failure  	failure  	 NN	I-NP
events  	events  	 NNS	I-NP
( 	( 	 -LRB-	O
RR  	RR  	 NNP	B-NP
0.51 	0.51 	 NNP	O
,  	,  	 ,	O
95 	95 	 CD	O
%  	%  	 NN	O
CI  	CI  	 NNP	O
0.37-0.71 	0.37-0.71 	 NNP	O
) 	) 	 -RRB-	O
.  	.  	 .	O
The  	The  	 DT	O
rates  	rates  	 NNS	O
of  	of  	 IN	O
CHF  	CHF  	 NNP	B-NP
in  	in  	 IN	O
SHEP  	SHEP  	 NNP	B-NP
participants  	participants  	 NNS	I-NP
treated  	treated  	 VBN	O
with  	with  	 IN	O
diuretics  	diuretics  	 NN	B-NP
and  	and  	 CC	O
placebo  	placebo  	 NN	O
were  	were  	 VBD	O
5  	5  	 CD	O
and  	and  	 CC	O
10  	10  	 CD	O
per  	per  	 IN	O
1,000  	1,000  	 CD	O
person-years 	person-years 	 NN	B-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
In  	In  	 IN	O
comparison 	comparison 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
rates  	rates  	 NNS	O
of  	of  	 IN	O
CHF  	CHF  	 NNP	B-NP
in  	in  	 IN	O
ALLHAT  	ALLHAT  	 NNP	B-NP
participants  	participants  	 NNS	I-NP
treated  	treated  	 VBN	O
with  	with  	 IN	O
diuretics  	diuretics  	 NN	B-NP
and  	and  	 CC	O
doxazosin  	doxazosin  	 NNS	B-NP
were  	were  	 VBD	O
10  	10  	 CD	O
and  	and  	 CC	O
20  	20  	 CD	O
per  	per  	 IN	O
1,000  	1,000  	 CD	O
person-years 	person-years 	 NN	B-NP
,  	,  	 ,	O
respectively 	respectively 	 RB	O
.  	.  	 .	O
If  	If  	 IN	O
low-dose  	low-dose  	 JJ	B-NP
chlorthalidone  	chlorthalidone  	 NN	I-NP
has  	has  	 VBZ	O
a  	a  	 DT	O
similar  	similar  	 JJ	O
risk  	risk  	 NN	B-NP
reduction  	reduction  	 NN	I-NP
in  	in  	 IN	O
the  	the  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
population 	population 	 NN	I-NP
,  	,  	 ,	O
and  	and  	 CC	O
halves  	halves  	 VBZ	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
clinical  	clinical  	 JJ	B-NP
heart  	heart  	 NN	I-NP
failure  	failure  	 NN	I-NP
events  	events  	 NNS	I-NP
compared  	compared  	 VBN	O
to  	to  	 TO	O
no  	no  	 DT	O
therapy 	therapy 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
effect  	effect  	 NN	O
of  	of  	 IN	O
doxazosin  	doxazosin  	 NNS	B-NP
would  	would  	 MD	O
be  	be  	 VB	O
comparable  	comparable  	 JJ	O
to  	to  	 TO	O
that  	that  	 DT	O
of  	of  	 IN	O
the  	the  	 DT	O
placebo  	placebo  	 JJ	O
arm  	arm  	 NN	O
in  	in  	 IN	O
the  	the  	 DT	O
SHEP  	SHEP  	 NNP	B-NP
trial 	trial 	 NN	I-NP
.  	.  	 .	O
Conclusions  	Conclusions  	 NNS	O
The  	The  	 DT	O
report  	report  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
doxazosin  	doxazosin  	 JJ	B-NP
arm  	arm  	 NN	I-NP
termination  	termination  	 NN	I-NP
in  	in  	 IN	O
ALLHAT  	ALLHAT  	 NNP	B-NP
was  	was  	 VBD	O
published  	published  	 VBN	O
in  	in  	 IN	O
April 	April 	 NNP	O
,  	,  	 ,	O
2000 	2000 	 CD	O
.  	.  	 .	O
At  	At  	 IN	O
that  	that  	 DT	O
time 	time 	 NN	O
,  	,  	 ,	O
the  	the  	 DT	O
results  	results  	 NNS	O
of  	of  	 IN	O
the  	the  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
trial  	trial  	 NN	I-NP
were  	were  	 VBD	O
unexpected 	unexpected 	 JJ	O
,  	,  	 ,	O
given  	given  	 VBN	O
the  	the  	 DT	O
potential  	potential  	 JJ	B-NP
association  	association  	 NN	I-NP
between  	between  	 IN	O
high  	high  	 JJ	O
dose  	dose  	 NN	B-NP
diuretics  	diuretics  	 NNS	I-NP
and  	and  	 CC	O
the  	the  	 DT	O
risk  	risk  	 NN	O
of  	of  	 IN	O
sudden  	sudden  	 JJ	O
death  	death  	 NN	O
[  	[  	 -LRB-	O
22  	22  	 CD	O
]  	]  	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
favorable  	favorable  	 JJ	O
effect  	effect  	 NN	O
of  	of  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
on  	on  	 IN	O
lipid  	lipid  	 JJ	B-NP
profiles  	profiles  	 NNS	I-NP
[  	[  	 -LRB-	O
14  	14  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Comparing  	Comparing  	 VBG	B-NP
data  	data  	 NNS	I-NP
from  	from  	 IN	O
other  	other  	 JJ	O
studies  	studies  	 NNS	O
suggests  	suggests  	 VBZ	O
the  	the  	 DT	O
possibility  	possibility  	 NN	O
that  	that  	 IN	O
the  	the  	 DT	O
beneficial  	beneficial  	 JJ	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
for  	for  	 IN	I-NP
lowering  	lowering  	 VBG	I-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
may  	may  	 MD	O
be  	be  	 VB	O
nullified  	nullified  	 VBN	O
by  	by  	 IN	O
a  	a  	 DT	O
negative  	negative  	 JJ	B-NP
effect 	effect 	 NN	I-NP
,  	,  	 ,	O
or  	or  	 CC	O
that  	that  	 DT	O
other  	other  	 JJ	O
antihypertensives  	antihypertensives  	 NNS	B-NP
have  	have  	 VBP	O
positive  	positive  	 JJ	B-NP
actions  	actions  	 NNS	I-NP
beyond  	beyond  	 IN	O
their  	their  	 PRP$	O
antihypertensive  	antihypertensive  	 JJ	B-NP
effects 	effects 	 NNS	I-NP
.  	.  	 .	O
Those  	Those  	 DT	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
doxazosin  	doxazosin  	 NN	B-NP
in  	in  	 IN	O
ALLHAT  	ALLHAT  	 NNP	B-NP
had  	had  	 VBD	O
a  	a  	 DT	O
mean  	mean  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
that  	that  	 WDT	O
was  	was  	 VBD	O
2  	2  	 CD	O
to  	to  	 TO	O
3  	3  	 CD	O
mmHg  	mmHg  	 JJ	B-NP
higher  	higher  	 JJR	I-NP
than  	than  	 IN	O
the  	the  	 DT	O
mean  	mean  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
of  	of  	 IN	O
those  	those  	 DT	O
treated  	treated  	 VBN	O
with  	with  	 IN	O
chlorthalidone 	chlorthalidone 	 NN	B-NP
.  	.  	 .	O
Based  	Based  	 VBN	O
on  	on  	 IN	O
Framingham  	Framingham  	 NNP	B-NP
Heart  	Heart  	 NNP	I-NP
Study  	Study  	 NNP	I-NP
logistic  	logistic  	 FW	I-NP
regression  	regression  	 FW	I-NP
coefficients 	coefficients 	 FW	I-NP
,  	,  	 ,	O
this  	this  	 DT	O
2  	2  	 CD	O
to  	to  	 TO	O
3  	3  	 CD	O
mmHg  	mmHg  	 JJ	B-NP
difference  	difference  	 NN	I-NP
in  	in  	 IN	O
systolic  	systolic  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
is  	is  	 VBZ	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
an  	an  	 DT	O
increased  	increased  	 JJ	O
relative  	relative  	 JJ	B-NP
risk  	risk  	 NN	I-NP
of  	of  	 IN	O
only  	only  	 RB	O
1.06  	1.06  	 CD	O
to  	to  	 TO	O
1.09  	1.09  	 CD	O
[  	[  	 -LRB-	O
23  	23  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
From  	From  	 IN	O
available  	available  	 JJ	O
data 	data 	 NNS	O
,  	,  	 ,	O
it  	it  	 PRP	O
appears  	appears  	 VBZ	O
that  	that  	 IN	O
this  	this  	 DT	O
average  	average  	 JJ	O
difference  	difference  	 NN	O
in  	in  	 IN	O
systolic  	systolic  	 JJ	B-NP
blood  	blood  	 NN	I-NP
pressure  	pressure  	 NN	I-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
large  	large  	 JJ	O
enough  	enough  	 JJ	O
to  	to  	 TO	O
double  	double  	 VB	O
the  	the  	 DT	O
average  	average  	 JJ	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
CHF 	CHF 	 NNP	B-NP
.  	.  	 .	O
The  	The  	 DT	O
literature  	literature  	 NN	O
suggests  	suggests  	 VBZ	O
several  	several  	 JJ	O
mechanisms  	mechanisms  	 NNS	O
by  	by  	 IN	O
which  	which  	 WDT	O
peripheral  	peripheral  	 VBD	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
in  	in  	 IN	O
general  	general  	 JJ	O
and  	and  	 CC	O
doxazosin  	doxazosin  	 NN	B-NP
in  	in  	 IN	O
particular  	particular  	 JJ	O
might  	might  	 MD	O
prove  	prove  	 VB	O
inferior  	inferior  	 JJ	O
to  	to  	 TO	O
other  	other  	 JJ	O
types  	types  	 NNS	O
of  	of  	 IN	O
antihypertensive  	antihypertensive  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
They  	They  	 PRP	O
are  	are  	 VBP	O
associated  	associated  	 VBN	O
with  	with  	 IN	O
a  	a  	 DT	O
mild  	mild  	 JJ	O
volume  	volume  	 NN	B-NP
expansion 	expansion 	 NN	I-NP
,  	,  	 ,	O
which  	which  	 WDT	O
may  	may  	 MD	O
precipitate  	precipitate  	 VB	O
the  	the  	 DT	O
clinical  	clinical  	 JJ	B-NP
presentation  	presentation  	 NN	I-NP
of  	of  	 IN	I-NP
heart  	heart  	 NN	I-NP
failure  	failure  	 NN	I-NP
in  	in  	 IN	O
those  	those  	 DT	O
with  	with  	 IN	O
subclinical  	subclinical  	 JJ	B-NP
disease 	disease 	 NN	I-NP
.  	.  	 .	O
If  	If  	 IN	O
this  	this  	 DT	O
is  	is  	 VBZ	O
the  	the  	 DT	O
mechanism  	mechanism  	 NN	O
responsible  	responsible  	 JJ	O
for  	for  	 IN	O
increasing  	increasing  	 VBG	O
the  	the  	 DT	O
incidence  	incidence  	 NN	O
of  	of  	 IN	O
CHF  	CHF  	 NNP	B-NP
in  	in  	 IN	O
the  	the  	 DT	O
ALLHAT  	ALLHAT  	 NNP	B-NP
trial 	trial 	 NN	I-NP
,  	,  	 ,	O
it  	it  	 PRP	O
would  	would  	 MD	O
be  	be  	 VB	O
consistent  	consistent  	 JJ	O
with  	with  	 IN	O
the  	the  	 DT	O
early  	early  	 JJ	O
divergence  	divergence  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
Kaplan-Meier  	Kaplan-Meier  	 JJ	B-NP
curves  	curves  	 NN	I-NP
in  	in  	 IN	O
that  	that  	 DT	O
study 	study 	 NN	O
.  	.  	 .	O
Peripheral  	Peripheral  	 NNP	B-NP
alpha-1  	alpha-1  	 NNP	I-NP
antagonists  	antagonists  	 VBD	I-NP
also  	also  	 RB	O
cause  	cause  	 VB	O
neurohormonal  	neurohormonal  	 JJ	B-NP
changes  	changes  	 NNS	I-NP
during  	during  	 IN	O
chronic  	chronic  	 JJ	B-NP
therapy 	therapy 	 NN	I-NP
.  	.  	 .	O
The  	The  	 DT	O
long-term  	long-term  	 JJ	O
ramifications  	ramifications  	 NNS	B-NP
of  	of  	 IN	O
these  	these  	 DT	O
changes  	changes  	 NNS	O
for  	for  	 IN	O
patients  	patients  	 NNS	O
being  	being  	 VBG	O
treated  	treated  	 VBN	O
for  	for  	 IN	O
hypertension  	hypertension  	 NNS	O
are  	are  	 VBP	O
not  	not  	 RB	O
known 	known 	 VBN	O
.  	.  	 .	O
These  	These  	 DT	O
drugs  	drugs  	 NNS	O
appear  	appear  	 VBP	O
to  	to  	 TO	O
cause  	cause  	 VB	O
increases  	increases  	 NNS	O
in  	in  	 IN	O
norepinephrine 	norepinephrine 	 NN	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
this  	this  	 DT	O
increase  	increase  	 NN	O
may  	may  	 MD	O
nullify  	nullify  	 VB	O
the  	the  	 DT	O
beneficial  	beneficial  	 JJ	O
effect  	effect  	 NN	O
of  	of  	 IN	O
lowered  	lowered  	 JJ	O
blood  	blood  	 NN	O
pressure  	pressure  	 NN	O
on  	on  	 IN	O
the  	the  	 DT	O
occurrence  	occurrence  	 NN	O
of  	of  	 IN	O
CHF 	CHF 	 NNP	B-NP
.  	.  	 .	O
Not  	Not  	 RB	O
only  	only  	 RB	O
are  	are  	 VBP	O
increased  	increased  	 VBN	B-NP
plasma  	plasma  	 NNS	I-NP
catecholamines  	catecholamines  	 VBP	O
a  	a  	 DT	O
central  	central  	 JJ	O
feature  	feature  	 NN	O
in  	in  	 IN	O
heart  	heart  	 NN	B-NP
failure 	failure 	 NN	I-NP
,  	,  	 ,	O
they  	they  	 PRP	O
are  	are  	 VBP	O
now  	now  	 RB	O
a  	a  	 DT	O
recommended  	recommended  	 JJ	O
target  	target  	 NN	O
for  	for  	 IN	O
effective  	effective  	 JJ	O
life-prolonging  	life-prolonging  	 JJ	B-NP
therapy  	therapy  	 NN	I-NP
[  	[  	 -LRB-	O
24  	24  	 CD	O
25  	25  	 CD	O
26  	26  	 CD	O
]  	]  	 -RRB-	O
.  	.  	 .	O
Given  	Given  	 VBN	O
that  	that  	 IN	O
doxazosin  	doxazosin  	 NN	B-NP
is  	is  	 VBZ	O
not  	not  	 RB	O
as  	as  	 IN	O
effective  	effective  	 JJ	O
as  	as  	 IN	O
chlorthalidone  	chlorthalidone  	 NN	B-NP
in  	in  	 IN	O
reducing  	reducing  	 VBG	O
the  	the  	 DT	O
cardiovascular  	cardiovascular  	 JJ	B-NP
complications  	complications  	 NNS	I-NP
of  	of  	 IN	O
hypertension 	hypertension 	 NN	O
,  	,  	 ,	O
several  	several  	 JJ	O
questions  	questions  	 NNS	O
remain 	remain 	 VBP	O
.  	.  	 .	O
There  	There  	 EX	O
is  	is  	 VBZ	O
still  	still  	 RB	O
a  	a  	 DT	O
paucity  	paucity  	 NN	O
of  	of  	 IN	O
information  	information  	 NN	O
regarding  	regarding  	 VBG	O
the  	the  	 DT	O
absolute  	absolute  	 JJ	B-NP
risk  	risk  	 NN	I-NP
reduction  	reduction  	 NN	I-NP
for  	for  	 IN	I-NP
clinical  	clinical  	 JJ	I-NP
heart  	heart  	 NN	I-NP
failure  	failure  	 NN	I-NP
or  	or  	 CC	O
other  	other  	 JJ	O
cardiovascular  	cardiovascular  	 JJ	B-NP
events  	events  	 NNS	I-NP
afforded  	afforded  	 VBN	O
by  	by  	 IN	O
peripheral  	peripheral  	 JJ	B-NP
alpha-1  	alpha-1  	 CD	I-NP
antagonists  	antagonists  	 NNS	I-NP
in  	in  	 IN	O
a  	a  	 DT	O
variety  	variety  	 NN	O
of  	of  	 IN	O
populations 	populations 	 NNS	O
.  	.  	 .	O
Differentiation  	Differentiation  	 NNP	B-NP
of  	of  	 IN	O
the  	the  	 DT	O
mechanism  	mechanism  	 NN	O
for  	for  	 IN	O
reduced  	reduced  	 JJ	O
protection  	protection  	 NN	O
compared  	compared  	 VBN	O
to  	to  	 TO	O
diuretics  	diuretics  	 NNS	B-NP
would  	would  	 MD	O
be  	be  	 VB	O
interesting  	interesting  	 JJ	O
but  	but  	 CC	O
difficult  	difficult  	 JJ	O
to  	to  	 TO	O
accomplish 	accomplish 	 VB	O
.  	.  	 .	O
For  	For  	 IN	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
in  	in  	 IN	O
particular 	particular 	 JJ	O
,  	,  	 ,	O
the  	the  	 DT	O
increase  	increase  	 NN	O
in  	in  	 IN	O
symptomatic  	symptomatic  	 JJ	B-NP
episodes  	episodes  	 NNS	I-NP
of  	of  	 IN	O
CHF  	CHF  	 NNP	B-NP
may  	may  	 MD	O
be  	be  	 VB	O
due  	due  	 JJ	O
to  	to  	 TO	O
hemodynamic  	hemodynamic  	 VB	O
effects  	effects  	 NNS	O
of  	of  	 IN	O
doxazosin  	doxazosin  	 JJ	B-NP
unmasking  	unmasking  	 JJ	I-NP
incipient  	incipient  	 JJ	I-NP
heart  	heart  	 NN	I-NP
failure 	failure 	 NN	I-NP
,  	,  	 ,	O
direct  	direct  	 JJ	O
myocardial  	myocardial  	 JJ	B-NP
injury 	injury 	 NN	I-NP
,  	,  	 ,	O
or  	or  	 CC	O
both 	both 	 DT	O
.  	.  	 .	O
Chronic  	Chronic  	 JJ	B-NP
volume  	volume  	 NN	I-NP
loading  	loading  	 NN	I-NP
may  	may  	 MD	O
not  	not  	 RB	O
only  	only  	 RB	O
unmask  	unmask  	 VB	O
subclinical  	subclinical  	 JJ	B-NP
ventricular  	ventricular  	 JJ	I-NP
dysfunction 	dysfunction 	 NN	I-NP
,  	,  	 ,	O
but  	but  	 CC	O
may  	may  	 MD	O
possibly  	possibly  	 RB	O
contribute  	contribute  	 VB	O
to  	to  	 TO	O
worsening  	worsening  	 VB	O
ventricular  	ventricular  	 JJ	B-NP
function  	function  	 NN	I-NP
over  	over  	 IN	O
time 	time 	 NN	O
.  	.  	 .	O
Whatever  	Whatever  	 JJ	O
mechanisms  	mechanisms  	 NNS	O
were  	were  	 VBD	O
responsible  	responsible  	 JJ	O
for  	for  	 IN	O
the  	the  	 DT	O
heart  	heart  	 NN	B-NP
failure  	failure  	 NN	I-NP
findings  	findings  	 NNS	I-NP
in  	in  	 IN	O
ALLHAT 	ALLHAT 	 NNP	B-NP
,  	,  	 ,	O
the  	the  	 DT	O
results  	results  	 NNS	O
support  	support  	 VBP	O
the  	the  	 DT	O
current  	current  	 JJ	O
national  	national  	 JJ	O
recommendations  	recommendations  	 NNS	B-NP
to  	to  	 TO	O
use  	use  	 VB	O
low-dose  	low-dose  	 JJ	B-NP
diuretics  	diuretics  	 NN	I-NP
or  	or  	 CC	O
beta-blockers  	beta-blockers  	 JJ	B-NP
as  	as  	 IN	O
first  	first  	 JJ	O
line  	line  	 NN	B-NP
agents  	agents  	 NNS	I-NP
for  	for  	 IN	I-NP
the  	the  	 DT	I-NP
pharmacologic  	pharmacologic  	 JJ	I-NP
treatment  	treatment  	 NN	I-NP
of  	of  	 IN	O
uncomplicated  	uncomplicated  	 JJ	O
hypertension 	hypertension 	 NN	O
.  	.  	 .	O
Competing  	Competing  	 VBG	B-NP
Interests  	Interests  	 NNP	I-NP
Dr.  	Dr.  	 NNP	I-NP
Psaty  	Psaty  	 NNP	O
was  	was  	 VBD	O
a  	a  	 DT	O
Merck 	Merck 	 NNP	B-NP
/ 	/ 	 NNP	I-NP
SER  	SER  	 NNP	I-NP
Clinical  	Clinical  	 NNP	I-NP
Epidemiology  	Epidemiology  	 NNP	I-NP
Fellow  	Fellow  	 NNP	I-NP
( 	( 	 -LRB-	O
co-sponsored  	co-sponsored  	 VBN	O
by  	by  	 IN	O
the  	the  	 DT	O
Merck  	Merck  	 NNP	O
Co 	Co 	 NNP	O
.  	.  	 .	O
Foundation 	Foundation 	 NNP	O
,  	,  	 ,	O
Rahway 	Rahway 	 NNP	B-NP
,  	,  	 ,	O
NJ 	NJ 	 NNP	B-NP
,  	,  	 ,	O
and  	and  	 CC	O
the  	the  	 DT	O
Society  	Society  	 NNP	O
for  	for  	 IN	O
Epidemiologic  	Epidemiologic  	 NNP	B-NP
Research 	Research 	 NNP	I-NP
,  	,  	 ,	O
Baltimore 	Baltimore 	 NNP	O
,  	,  	 ,	O
MD 	MD 	 NNP	O
) 	) 	 -RRB-	O
,  	,  	 ,	O
and  	and  	 CC	O
a  	a  	 DT	O
member  	member  	 NN	O
of  	of  	 IN	O
the  	the  	 DT	O
Events  	Events  	 NNP	O
Committee  	Committee  	 NNP	O
of  	of  	 IN	O
the  	the  	 DT	O
HERS  	HERS  	 NNP	O
trial  	trial  	 NN	O
funded  	funded  	 VBN	O
by  	by  	 IN	O
Wyeth  	Wyeth  	 NNP	B-NP
Ay  	Ay  	 NNP	O
erst 	erst 	 NN	B-NP
.  	.  	 .	O
